C12N 2760/18611
Respirovirus
Official title: Respirovirus, e.g. Bovine, human parainfluenza 1,3
C12N2760/18611 (Respirovirus) appears on 218 US grants and 241 published applications in this corpus.
Search patents in C12N- Granted patents
- 218
- Published applications
- 241
- Assignees
- 148
- Inventors
- 407
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 7 | 0 |
| 1999 | 8 | 0 |
| 2000 | 14 | 0 |
| 2001 | 12 | 0 |
| 2002 | 6 | 5 |
| 2003 | 2 | 11 |
| 2004 | 8 | 13 |
| 2005 | 3 | 9 |
| 2006 | 2 | 6 |
| 2007 | 8 | 11 |
| 2008 | 8 | 21 |
| 2009 | 8 | 7 |
| 2010 | 11 | 13 |
| 2011 | 8 | 12 |
| 2012 | 1 | 8 |
| 2013 | 5 | 7 |
| 2014 | 8 | 12 |
| 2015 | 7 | 7 |
| 2016 | 8 | 11 |
| 2017 | 14 | 6 |
| 2018 | 4 | 8 |
| 2019 | 9 | 5 |
| 2020 | 6 | 16 |
| 2021 | 7 | 4 |
| 2022 | 7 | 11 |
| 2023 | 3 | 7 |
| 2024 | 4 | 12 |
| 2025 | 7 | 9 |
| 2026 | 5 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18634Use of virus or viral component as vaccineIndexing code118
- C12N 2760/18622New viral proteins or individual genes, new structural or functional aspects ofIndexing code108
- C12N 2760/18641Use of virus, viral particle or viral elements as a vectorIndexing code40
- C12N 2760/18661Methods of inactivation or attenuationIndexing code23
- C12N 2760/18621Viruses as suchIndexing code16
- C12N 2760/18651Methods of production or purification of viral materialIndexing code15
- C12N 2760/18671Demonstrated in vivo effectIndexing code11
- C12N 2760/18632Use of virus as therapeutic agent, other than vaccineIndexing code3
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Betacoronavirus mRNA vaccines19 May 2026US 12,629,412 B2ModernaTX, Inc.
- Betacoronavirus mRNA vaccines17 Feb 2026US 12,551,734 B2ModernaTX, Inc.
- Method for producing induced pluripotent stem cells20 Jan 2026US 12,529,035 B1National University Corporation Kobe University
- Betacoronavirus RNA vaccines13 Jan 2026US 12,521,577 B2ModernaTX, Inc.
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Programmable miRNA-Dependent Gene Expression1 Oct 2026US 2026/0295089 A1New York University
- Stabilized pre-fusion piv3 f proteins13 Aug 2026US 2026/0232789 A1Msd International Business GmbH
- Pre-fusion human piv1 f proteins21 May 2026US 2026/0139011 A1Janssen Vaccines & Prevention B. V.
- Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof14 May 2026US 2026/0131011 A1Decoy Therapeutics Inc.
Most cited
By later US patents
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- DNA transfection system for the generation of infectious influenza virus91US 6,951,754 B2St. Jude Children?S Research Hospital · 2005
- Modified live BRSV vaccine77US 5,733,555 AAmerican Home Products Corporation · 1998
- Metapneumovirus strains and their use in vaccine formulations and sequences74US 8,722,341 B2MedImmune Vaccines, Inc. · 2014
- Viral glycoprotein subunit vaccine69US 4,790,987 AResearch Corporation · 1988